[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573564":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":31,"locations":41,"responsibleParty":98,"collaborators":11,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":11,"eligibilityCriteria":106,"healthyVolunteers":102,"sex":107,"minAge":108,"maxAge":11,"enrollmentInfo":109,"targetDuration":11,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"SPARK Biopharma","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"SB17170 of A mg, Single dose","EXPERIMENTAL",null,[13],"Drug: SB17170",{"label":15,"type":10,"description":11,"interventionNames":16},"SB17170 of B mg, Single dose",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Placebo","PLACEBO_COMPARATOR",[21],"Drug: Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","SB17170","Taking SB17170 orally once a day",[9,15],{"type":24,"name":18,"description":29,"armGroupLabels":30,"otherNames":11},"Taking Placebo orally once a day",[18],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Seong Yun Bang","CONTACT","+82-2-887-8032","sybang@sparkbio.co.kr",{"name":38,"role":34,"phone":39,"phoneExt":11,"email":40},"Yu Jin Choi","+82-2-887-9972","yjchoi@sparkbio.co.kr",[42,56,67,79,87],{"facility":43,"status":44,"city":45,"state":11,"zip":11,"country":46,"countryCode":11,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Myong Ji Hospital","RECRUITING","Goyang","South Korea",{"type":48,"coordinates":49},"Point",[50,51],127.19731,36.21689,{"lat":51,"lon":50},[54],{"name":55,"role":34,"phone":11,"phoneExt":11,"email":11},"Wonil Choi, M.D.",{"facility":57,"status":44,"city":58,"state":11,"zip":11,"country":46,"countryCode":11,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Chung-Ang University Gwangmyeong Hospital","Gwangmyeong",{"type":48,"coordinates":60},[61,62],126.86639,37.47722,{"lat":62,"lon":61},[65],{"name":66,"role":34,"phone":11,"phoneExt":11,"email":11},"Jin Young Huh",{"facility":68,"status":69,"city":70,"state":11,"zip":11,"country":46,"countryCode":11,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Seoul Asan Hospital","NOT_YET_RECRUITING","Seoul",{"type":48,"coordinates":72},[73,74],126.9784,37.566,{"lat":74,"lon":73},[77],{"name":78,"role":34,"phone":11,"phoneExt":11,"email":11},"Jin Woo Song, M.D.",{"facility":80,"status":69,"city":70,"state":11,"zip":11,"country":46,"countryCode":11,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"The Catholic Univ. of Korea Seoul St. Mary's Hospital",{"type":48,"coordinates":82},[73,74],{"lat":74,"lon":73},[85],{"name":86,"role":34,"phone":11,"phoneExt":11,"email":11},"Yong Suk Jo, M.D.",{"facility":88,"status":69,"city":89,"state":11,"zip":11,"country":46,"countryCode":11,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Ajou University Hospital","Suwon",{"type":48,"coordinates":91},[92,93],127.00889,37.29111,{"lat":93,"lon":92},[96],{"name":97,"role":34,"phone":11,"phoneExt":11,"email":11},"Joo Hun Park, M.D.",{"type":99,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100573564","phase-2-sb17170-phase-2-trial-in-ipf-patients-100573564",false,"NCT06747923","SB17170 Phase 2 Trial in IPF Patients","A Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter, Exploratory Phase IIa Clinical Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of SB17170 in Idiopathic Pulmonary Fibrosis (IPF) Patients.","Inclusion Criteria:\n\n1. Adult male\u002Ffemale 40 years or older at the time of obtaining informed consent\n2. Patients diagnosed with idiopathic pulmonary fibrosis who meet the following criteria:\n\n   * Patients with idiopathic pulmonary fibrosis who are confirmed by chest High-Resolution Computed Tomography (HRCT) scan\n   * Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT pattern consistent with a diagnosis of idiopathic pulmonary fibrosis confirmed through central reading of chest HRCT before the baseline visit\n3. Patients with a history of idiopathic pulmonary fibrosis treatment who meet the defined criteria\n4. Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at the screening visit\n5. Patients meeting pulmonary function test criteria at the screening visit\n6. Patients who have received the explanation of this clinical trial and voluntarily agreed and signed the informed consent form\n\nExclusion Criteria:\n\n1. When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and\u002For other clinically significant lung abnormalities\n2. Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and\u002For during the screening period\n3. Patients with lower respiratory tract infections requiring antibiotic treatment\n4. Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial\n5. Patients with a history of malignancy or documented evidence of active or suspected malignancy within 5 years prior to screening\n6. Patients with evidence of active infection\n7. Patients with the following cardiovascular and cerebrovascular diseases at the time of screening:\n\n   * Severe hypertension within 3 months\n   * Myocardial infarction or unstable angina within 6 months\n   * History of thrombotic events within 6 months\n   * Diagnosis of heart failure within 6 months\n8. Patients with pulmonary hypertension\n9. Patients who are unable to take drugs orally or have a history of major gastrointestinal surgery or pathological findings that may affect the absorption of the investigational product\n10. Patients with Human Immunodeficiency Virus (HIV) infection or active hepatitis B or C","ALL","40 Years",{"count":110,"type":111},30,"ESTIMATED","INTERVENTIONAL",[114],"PHASE2","This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.",[117,118,119],"IPF","Idiopathic Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis (IPF)",[121],"HMGB1","2025-11-17",{"date":124,"type":125},"2025-11-19","ACTUAL",{"date":127,"type":125},"2025-01-27",{"date":129,"type":111},"2026-10-31",{"name":5,"class":6},5]